Bipolar Proteomic Assay Validation Study

NCT02746367 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 261

Last updated 2020-05-14

No results posted yet for this study

Summary

The purpose of this study is to validate a set of signatures, based on a panel of proteomic markers, that discriminate BDI, BDII, and MDD in people seeking treatment for a depressive episode.

Conditions

  • Major Depressive Disorder, Bipolar I and Bipolar II

Interventions

OTHER

Diagnostic test (LDT)

Proteomic assay

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-11-08
Completion
2018-11-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02746367 on ClinicalTrials.gov